HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer (NCT07543536) | Sun Yat-sen University | 2026-06-08 |
Track HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.